論文 - 青木　大輔

Re: Starting a uterus transplantation service: notes from a small island

Kisu, I., Matoba, Y., Banno, K. and Aoki, D.

Bjog 125 （ 4 ） 515 - 516 2018年03月

ISSN  1470-0328

• Access to Document (DOI)

Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer

Mikami, M., Shida, M., Shibata, T., Katabuchi, H., Kigawa, J., Aoki, D. and Yaegashi, N.

J Gynecol Oncol 29 （ 2 ） e23 2018年03月

ISSN  2005-0380

　概要を見る

OBJECTIVE: The Japan Society of Gynecologic Oncology (JSGO) initiated a nation-wide training system for the education and certification for gynecologic oncologists in 2005. To assess the impact of the quality of the JSGO-accredited institutions, JSGO undertook an analysis of the Uterine Cervical Cancer Registry of the Japan Society of Obstetrics and Gynecology (JSOG) to determine the effectiveness of the JSGO-accredited institutions on the treatment and survival of women with cervical cancer. METHODS: The effectiveness of 119 JSGO-accredited institutions and 125 non-JSGO-accredited institutions on the treatment and survival of women with cervical cancer were compared by analyzing the tumor characteristics, treatment patterns, and survival outcomes of women with stage T1B-T4 cervical cancer utilizing the data in the JSOG nation-wide registry for cervical cancer (2006-2009). RESULTS: A total of 14,185 eligible women were identified: 10,920 (77.0%) cases for 119 JSGO-accredited institutions and 3,265 (23.0%) cases for 125 non-accredited institutions. A multivariate analysis showed that age, stage, histology type, and treatment pattern were independently associated with mortality. Moreover, women who received treatment at the JSGO-accredited institutions had a significantly decreased mortality risk compared to non-accredited institutions (adjusted hazard ratio [aHR]=0.843; 95% confidence interval [CI]=0.784-0.905). Similar findings on multivariate analysis were seen among subset of women who received surgery alone (aHR=0.552; 95% CI=0.393-0.775) and among women who received radiotherapy (aHR=0.845; 95% CI=0.766-0.931). CONCLUSION: Successful implementation of gynecologic oncology accrediting institution was associated with improved survival outcome of women with cervical cancer in Japan.

• Access to Document (DOI)

The 5th Biennial Meeting of the Asian Society of Gynecologic Oncology, November 30th to December 2nd, 2017

Tominaga, E., Kobayashi, Y. and Aoki, D.

J Gynecol Oncol 29 （ 2 ） e33 2018年03月

ISSN  2005-0380

• Access to Document (DOI)

Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

Yamagami, W., Susumu, N., Makabe, T., Sakai, K., Nomura, H., Kataoka, F., Hirasawa, A., Banno, K. and Aoki, D.

J Gynecol Oncol 29 （ 2 ） e21 2018年03月

ISSN  2005-0380

　概要を見る

OBJECTIVE: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking. We aimed to clarify the outcomes of repeated MPA therapy in cases of intrauterine recurrence after fertility-preserving therapy with MPA against AEH/early G1. METHODS: Patients with AEH or stage IA well-differentiated endometrioid carcinoma without myometrial invasion who underwent first-line MPA therapy for primary lesions or intrauterine recurrence were divided into initial treatment and repeated treatment groups (162 and 82 patients, respectively). Oral MPA administration (400-600 mg/day) was continued until pathological tumor disappearance. Data regarding clinicopathological factors, adverse events, and outcomes following the initial and repeated hormonal treatments were extracted from medical records and analyzed. RESULTS: Complete response rates in the initial and repeated treatment groups were 98.5% and 96.4%, respectively, among patients with AEH, and were 90.7% and 98.1%, respectively, among patients with G1. In the initial treatment group, 5-year recurrence-free survival (RFS) rates were 53.7% and 33.2% among patients with AEH and G1, respectively. In the repeated treatment group, RFS rates were 14.0% and 11.2% among patients with AEH and G1, respectively. Among patients with AEH, the pregnancy rate tended to be lower in the repeated treatment group than in the initial treatment group (11.1% vs. 29.2%; p=0.107), while no significant group difference was observed among patients with G1 (20.8% vs. 22.7%). CONCLUSION: Repeated treatment is sufficiently effective for intrauterine recurrence after hormonal therapy for AEH/early G1.

• Access to Document (DOI)

ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death

Ueno M., Shiomi T., Mochizuki S., Chijiiwa M., Shimoda M., Kanai Y., Kataoka F., Hirasawa A., Susumu N., Aoki D., Okada Y.

Cancer Science （Cancer Science）  109 （ 2 ） 471 - 482 2018年02月

ISSN  1347-9032

　概要を見る

© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ADAMs (a disintegrin and metalloproteinases) are involved in various biological events such as cell adhesion, migration and invasion, membrane protein shedding and proteolysis. However, there have been no systematic studies on the expression of ADAMs in human ovarian carcinomas. We therefore examined mRNA expression of all the proteolytic ADAM species including ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, 33 and ADAMDEC1 in human ovarian carcinomas, and found that prototype membrane-anchored ADAM9m, but not secreted isoform ADAM9s, is significantly over-expressed in carcinomas than in control non-neoplastic ovarian tissue. Among the histological subtypes of serous, endometrioid, mucinous and clear cell carcinomas, ADAM9m expression was highest in clear cell carcinomas. Immunohistochemistry showed that all the clear cell carcinoma samples displayed ADAM9m primarily on the carcinoma cell membrane. By immunoblotting, ADAM9m was detected mainly in an active form in the clear cell carcinoma tissues. When two clear cell carcinoma cell lines (RMG-I and TOV21G cells) with ADAM9m expression were treated with cisplatin, viability was significantly reduced and apoptosis increased in ADAM9m knockdown cells compared with mock transfectants. In addition, treatment of the cells with neutralizing anti-ADAM9m antibody significantly decreased viability compared with non-immune IgG, whereas ADAM9m over-expression significantly increased viability compared with mock transfectants. Our data show, to the best of our knowledge, for the first time, that ADAM9m is over-expressed in an activated form in human ovarian clear cell carcinomas, and suggest that ADAM9m plays a key role in cisplatin resistance.

• Access to Document (DOI)

Radiation-induced angiosarcoma of the omentum diagnosed by laparoscopy: A case report

Kunitomi, H., Banno, K., Iseki, H., Sera, A., Miyauchi, A., Kobayashi, Y., Hayashi, S., Tominaga, E., Sasaki, A., Kawaida, M., Kameyama, K. and Aoki, D.

Mol Clin Oncol 8 （ 2 ） 264 - 268 2018年02月

ISSN  2049-9450

　概要を見る

Angiosarcoma is a rare malignant tumor with an aggressive clinical course and a poor prognosis. Intraperitoneal angiosarcoma, especially originating from the omentum, is extremely rare. We report a case of radiation-induced angiosarcoma of the omentum that arose in a 38-year-old female seven years after concurrent chemoradiotherapy for cervical cancer. The primary tumor was unknown until diagnostic laparoscopy revealed an unresectable omental mass. Pathological examination revealed high-grade malignant cells positive for endothelial markers. Although the small number of cases limits the consensus on optimal therapy for advanced angiosarcoma, the patient was managed successfully by taxane-based chemotherapy, leading to complete response and consequent complete cytoreductive surgery. Our report is the fifth case of radiation-induced angiosarcoma of the omentum, and all have developed after treatment for gynecologic cancer. Although very rare, this complication should be considered after radiation therapy in cancer treatment, particularly given the increasing importance of this therapy.

• Access to Document (DOI)

Erratum: Recent advances in the molecular mechanisms of Mayer-Rokitansky-Kuster-Hauser syndrome

Watanabe, K., Kobayashi, Y., Banno, K., Matoba, Y., Kunitomi, H., Nakamura, K., Adachi, M., Umene, K., Kisu, I., Tominaga, E. and Aoki, D.

Biomed Rep 8 （ 1 ） 106 2018年01月

ISSN  2049-9434

　概要を見る

[This corrects the article DOI: 10.3892/br.2017.929.].

• Access to Document (DOI)

HPV検査の活用法

村上 功，岩田 卓，森定 徹，青木大輔

臨床婦人科産科 72 （ 1 ） 150 - 157 2018年01月

共著

Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations

青木 大輔

Invest New Drugs 35 （ 6 ） 800 - 812 2017年12月

研究論文（学術雑誌）, 共著

SIM2l attenuates resistance to hypoxia and tumor growth by transcriptional suppression of HIF1A in uterine cervical squamous cell carcinoma

青木 大輔

Sci Rep 7 （ 1 ） 14574 2017年11月

研究論文（学術雑誌）, 共著

: . , 14(5):

青木 大輔

Oncol Lett 14 （ 5 ） 5107 - 5113 2017年11月

研究論文（学術雑誌）, 共著

: . ,

青木 大輔

Jpn J Clin Oncol 47 （ 11 ） 1019 - 1023 2017年11月

研究論文（学術雑誌）, 共著

Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer

Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, Nomura H, Masuda K, Susumu N, Tsuda H, Aoki D

Oncotarget 8 （ 68 ） 112258 - 112267 2017年11月

研究論文（学術雑誌）, 共著

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

青木 大輔

Ann Oncol 8 （ suppl 8 ） viii30 - viii35 2017年11月

共著, 査読有り

Allowable warm ischemic time and morphological and biochemical changes in uterine ischemia/reperfusion injury in cynomolgus macaque: a basic study for uterus transplantation

Kisu, I., Umeneo, K., Adachi, M., Emoto, K., Nogami, Y., Banno, K., Itagaki, I., Kawamoto, I., Nakagawa, T., Narita, H., Yoshida, A., Tsuchiya, H., Ogasawara, K. and Aoki, D.

Hum Reprod 32 （ 10 ） 2026 - 2035 2017年10月

研究論文（学術雑誌）, 共著,  ISSN  0268-1161

• Access to Document (DOI)

Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)

青木 大輔

Jpn J Clin Oncol 47 （ 10 ） 986 - 990 2017年10月

研究論文（学術雑誌）, 共著

Mid-trimester residual cervical length and the risk of preterm birth in pregnancies after abdominal radical trachelectomy: a retrospective analysis

Kasuga, Y., Miyakoshi, K., Nishio, H., Akiba, Y., Otani, T., Fukutake, M., Ikenoue, S., Ochiai, D., Matsumoto, T., Tanaka, K., Minegishi, K., Kuji, N., Roberts, R., Aoki, D. and Tanaka, M.

Bjog 124 （ 11 ） 1729 - 1735 2017年10月

研究論文（学術雑誌）, 共著,  ISSN  1470-0328

　概要を見る

OBJECTIVE: To investigate the association between mid-trimester residual cervical length (CL) and the risk of preterm birth in pregnancies after abdominal radical trachelectomy (RT). DESIGN: Retrospective cohort study. SETTING: University hospital. POPULATION: A total of 33 deliveries after 22 weeks' gestation in 30 women who underwent abdominal RT including prophylactic cervical cerclage and perinatal care between January 2002 and May 2016. METHODS: The association between mid-trimester residual CL (the distance between the cerclage and the external cervical os) and gestational age at delivery was investigated. Receiver-operating characteristics (ROC) curve analysis was performed to estimate the optimal cut-off values of the mid-trimester residual CL for the prediction of preterm birth. MAIN OUTCOME MEASURES: Preterm birth before 34 weeks' gestation. RESULTS: Mid-trimester residual CL showed a significant correlation with gestational age at delivery (r = 0.36, P < 0.05). There was a significant difference in residual CL between women who did and those who did not give birth before 34 weeks (P < 0.05). Mid-trimester residual CL < 13 mm was a good predictor of birth before 34 weeks, with a sensitivity of 67%, specificity of 75%, positive predictive value of 55% and negative predictive value of 86% (area under ROC curve, 0.75). CONCLUSIONS: Mid-trimester residual CL is significantly correlated with gestational age at delivery. Residual CL assessment could be used to reassure physicians and women that there is only a small chance of preterm birth in pregnancies after abdominal RT. TWEETABLE ABSTRACT: Mid-trimester residual cervical length is a good predictor of preterm birth after radical trachelectomy.

• Access to Document (DOI)

CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women

青木 大輔

Cancer Epidemiol 50 （ Pt A ） 60 - 67 2017年10月

研究論文（学術雑誌）, 共著

治療抵抗性排卵障害を契機に卵巣セルトリ・ライディッヒ細胞腫の診断に至った1例

國富晴子，升田博隆，瀬田康弘，飯島茂異人，片倉慧美，竹田 貴，吉政佑之，中村加奈子，三木史恵，青木大輔，田中　守

東京産科婦人科学会会誌 66 （ 44 ） 640 - 646 2017年10月

研究論文（学術雑誌）, 共著, 査読有り

子宮動脈塞栓術が奏功した帝王切開瘢痕部妊娠の1例

荘 慎太郎，松本 直，佐藤 佑，大谷利光，秋葉洋平，春日義史，池ノ上 学，落合大吾，宮越　敬，田中　守，青木大輔

東京産科婦人科学会会誌 66 （ 4 ） 647 - 651 2017年10月

研究論文（学術雑誌）, 共著